CN110025639A - Application of the yeast dextran composition in prevent constipation - Google Patents
Application of the yeast dextran composition in prevent constipation Download PDFInfo
- Publication number
- CN110025639A CN110025639A CN201910172666.8A CN201910172666A CN110025639A CN 110025639 A CN110025639 A CN 110025639A CN 201910172666 A CN201910172666 A CN 201910172666A CN 110025639 A CN110025639 A CN 110025639A
- Authority
- CN
- China
- Prior art keywords
- yeast dextran
- obtains
- saccharomyces cerevisiae
- probiotics
- constipation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000004808 Saccharomyces cerevisiae Species 0.000 title claims abstract description 95
- 229920002307 Dextran Polymers 0.000 title claims abstract description 65
- 206010010774 Constipation Diseases 0.000 title claims abstract description 60
- 239000000203 mixture Substances 0.000 title claims abstract description 11
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims abstract description 94
- 239000006041 probiotic Substances 0.000 claims abstract description 43
- 235000018291 probiotics Nutrition 0.000 claims abstract description 43
- 239000000843 powder Substances 0.000 claims abstract description 23
- 239000006228 supernatant Substances 0.000 claims abstract description 19
- 238000000227 grinding Methods 0.000 claims abstract description 17
- 102000004190 Enzymes Human genes 0.000 claims abstract description 15
- 108090000790 Enzymes Proteins 0.000 claims abstract description 15
- 239000004365 Protease Substances 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 15
- 239000007788 liquid Substances 0.000 claims abstract description 14
- 239000003513 alkali Substances 0.000 claims abstract description 13
- 239000012752 auxiliary agent Substances 0.000 claims abstract description 13
- 238000000498 ball milling Methods 0.000 claims abstract description 13
- 239000000287 crude extract Substances 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 12
- 230000009849 deactivation Effects 0.000 claims abstract description 11
- 238000000605 extraction Methods 0.000 claims abstract description 11
- 108091005804 Peptidases Proteins 0.000 claims abstract description 10
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract description 10
- 235000013305 food Nutrition 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 229940079593 drug Drugs 0.000 claims abstract description 8
- 239000000047 product Substances 0.000 claims abstract description 6
- 230000036541 health Effects 0.000 claims abstract description 5
- 238000010438 heat treatment Methods 0.000 claims abstract description 3
- 238000000926 separation method Methods 0.000 claims abstract description 3
- 239000013589 supplement Substances 0.000 claims abstract 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 42
- 230000000694 effects Effects 0.000 claims description 20
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 15
- 229940088598 enzyme Drugs 0.000 claims description 14
- 235000019419 proteases Nutrition 0.000 claims description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 241000894006 Bacteria Species 0.000 claims description 7
- 108010059892 Cellulase Proteins 0.000 claims description 6
- 229940106157 cellulase Drugs 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 108090000526 Papain Proteins 0.000 claims description 5
- 229940055729 papain Drugs 0.000 claims description 5
- 235000019834 papain Nutrition 0.000 claims description 5
- 235000002639 sodium chloride Nutrition 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 3
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 229940079827 sodium hydrogen sulfite Drugs 0.000 claims description 3
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 3
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 2
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims description 2
- 241000186012 Bifidobacterium breve Species 0.000 claims description 2
- 241001468229 Bifidobacterium thermophilum Species 0.000 claims description 2
- 244000241257 Cucumis melo Species 0.000 claims description 2
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 claims description 2
- 244000199866 Lactobacillus casei Species 0.000 claims description 2
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 2
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 2
- 238000001069 Raman spectroscopy Methods 0.000 claims description 2
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 claims description 2
- 229940017800 lactobacillus casei Drugs 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 claims description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 claims 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims 1
- 239000002023 wood Substances 0.000 claims 1
- 229920001503 Glucan Polymers 0.000 description 41
- 238000012360 testing method Methods 0.000 description 38
- 230000000968 intestinal effect Effects 0.000 description 32
- 241000699666 Mus <mouse, genus> Species 0.000 description 30
- 238000011049 filling Methods 0.000 description 27
- 150000004666 short chain fatty acids Chemical class 0.000 description 26
- 241000699670 Mus sp. Species 0.000 description 23
- 230000013872 defecation Effects 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- 239000002504 physiological saline solution Substances 0.000 description 17
- 108090000171 Interleukin-18 Proteins 0.000 description 15
- 229960001571 loperamide Drugs 0.000 description 14
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 14
- 238000005259 measurement Methods 0.000 description 13
- 230000002265 prevention Effects 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 241000186000 Bifidobacterium Species 0.000 description 11
- 102000003810 Interleukin-18 Human genes 0.000 description 11
- PGYPOBZJRVSMDS-UHFFFAOYSA-N loperamide hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 PGYPOBZJRVSMDS-UHFFFAOYSA-N 0.000 description 11
- 229960002983 loperamide hydrochloride Drugs 0.000 description 11
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 10
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 10
- -1 magnesia compound Chemical class 0.000 description 10
- 235000021391 short chain fatty acids Nutrition 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 230000005176 gastrointestinal motility Effects 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 108020004465 16S ribosomal RNA Proteins 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 239000000284 extract Substances 0.000 description 6
- 230000002550 fecal effect Effects 0.000 description 6
- 108090001082 glucan-binding proteins Proteins 0.000 description 6
- 230000000529 probiotic effect Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- YZMCKZRAOLZXAZ-UHFFFAOYSA-N sulfisomidine Chemical compound CC1=NC(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 YZMCKZRAOLZXAZ-UHFFFAOYSA-N 0.000 description 6
- 239000000654 additive Substances 0.000 description 5
- 230000000996 additive effect Effects 0.000 description 5
- 239000000976 ink Substances 0.000 description 5
- 210000001809 melena Anatomy 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000007405 data analysis Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000008944 intestinal immunity Effects 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 239000011049 pearl Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108010018924 Heme Oxygenase-1 Proteins 0.000 description 3
- 102100028006 Heme oxygenase 1 Human genes 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 230000007071 enzymatic hydrolysis Effects 0.000 description 3
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 235000013406 prebiotics Nutrition 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 244000215068 Acacia senegal Species 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 210000001187 pylorus Anatomy 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 235000007558 Avena sp Nutrition 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920000018 Callose Polymers 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 206010063036 Spinal cord oedema Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 241001078983 Tetradium ruticarpum Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003471 anti-radiation Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 210000003056 antler Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000001354 calcination Methods 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000001599 direct drying Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 238000012203 high throughput assay Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 238000013081 phylogenetic analysis Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000033772 system development Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/125—Casei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/31—Leuconostoc
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/513—Adolescentes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/515—Animalis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/519—Breve
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Middle application the present invention relates to yeast dextran composition in preparation for the drug, food and health care product of prevent constipation, wherein, the composition includes yeast dextran and probiotics, the yeast dextran and the weight ratio of probiotics are 1:1~10, the yeast dextran its be prepared by the following method acquisition: step 1) ball grinds: will Saccharomyces cerevisiae and grinding aid mix after carry out ball-milling treatment, obtain Saccharomyces cerevisiae powder；Step 2) alkali carries: Saccharomyces cerevisiae powder is extracted using auxiliary agent is extracted, and obtains yeast dextran crude extract；Step 3) purifying: protease hydrolyzed is added in the yeast dextran crude extract for taking step 2) to obtain, wherein extraction auxiliary agent is added by supplement, pH is maintained to stablize.Step 4) is dry: heating enzyme deactivation obtains enzymolysis liquid and obtains supernatant after separation, and dry supernatant obtains yeast dextran.
Description
Technical field
The present invention relates to a kind of preparations of yeast dextran composition for the drug of prevent constipation, food and health care product
Middle application
Background technique
Constipation of slow-remove type (slow transit constipation, STC) is one kind as caused by different pathological process
Complex clinical symptom is primarily referred to as defecation frequency is reduced, excrement is dry and hard, defecation is laborious etc., seriously affects patients ' life quality；Intestines
Road water metabolism disorder is the main pathogenesis of constipation, and especially colon Spinal Cord Oedema is abnormal has direct relation with it.It is main
Feature is that Colonic transit will pass through slowly, greatly time extension, with abdominal distension, is hard and dry.As modern people's rhythm of life adds
Fastly, living standard improves, and dietary structure changes and social population's aging, and the illness rate of STC is in the trend that is gradually increasing, and with
The growth at age and increase.Chronic constipation global incidence is about 14%, and wherein constipation of slow-remove type (STC) accounts for chronic special hair
First of property 4 kinds of hypotypes of constipation.Constipation not only seriously affects the life quality of patient, also with acute cardiovascular and cerebrovascular disease, dementia, knot
Carcinoma of the rectum etc. has close relationship.Postpartum, postoperative and old lie in bed have a possibility that adjoint constipation symptom, therefore accordingly add
Strong prevention and intervening measure can reduce hemorrhoid incidence, improve clinical patient outcome, reduce phase to timely treatment constipation
The generation for closing complication, finally significantly improves the quality of life of patient.
It is divided into Western medicine and Chinese medicine two major classes for the drug of prevent constipation currently on the market, Chinese medicine includes raw rhubarb, radish
Son, evodia rutaecarpa etc., Western medicine are mostly magnesia compound as main component, and long-term use is also easy to produce drug resistance, and with one
Serial side effect.Probiotics and increasingly become research in prebiotics 2 years nearly to the protective effect of intestinal flora and intestinal tissue
Hot spot.Yeast beta-dextran is natural prebiotics, is widely distributed in fungi, bacterium and plant cell wall, such as America Ji Song
In young pilose antler, mushroom, ganoderma lucidum, oat etc..Various biological activity is not only played in various organisms, but also between various biologies
Influence each other in also play a very important role, be play health-care effect main composition.It has now been found that its
With antitumor, anti-radiation, reducing blood lipid, norcholesterol, adjust blood glucose and prevention cardiovascular disease, repair cell, improvement enteron aisle
The effects of, it is research hotspot in recent years as efficient biological respinse regulatory factor (BRM).Beta glucan is a kind of structure
Complicated glucose polycomplex, is prevalent in the cell wall of bacterium, yeast, mushroom, cereal and seaweed etc..In vivo and
In vitro test it has been shown that separate sources β -1,3/1,6- glucan can enhance that host innate is immune and acquired immunity function
Can, the ability of enhancing pathogenic bacteria, virus and parasitic infection, is the immunopotentiator of great bioactivity.Saccharomyces cerevisiae
Glucan is the poly sugar compounds being found earliest, and the highest compound of polysaccharide of activity studied at present.
Summary of the invention
The present invention relates to yeast dextran compositions in drug, food and health care product of the preparation for prevent constipation
It include yeast dextran and probiotics using, wherein the composition, the weight ratio of yeast dextran and probiotics is
1:1~10, the yeast dextran are prepared by the following method acquisition:
Step 1) ball grinds: ball-milling treatment is carried out after high activity Saccharomyces cerevisiae and grinding aid are mixed, obtains bread
Yeast powder；
Step 2) alkali carries: Saccharomyces cerevisiae powder is extracted using auxiliary agent is extracted, and obtains yeast dextran crude extract, wherein institute
State extract auxiliary agent be selected from one of sodium chloride, sodium hydroxide, sodium bicarbonate, sodium hydrogensulfite and sodium bisulphate solution or
Two kinds of person or more；
Step 3) purifying: protease hydrolyzed is added, wherein passes through benefit in the yeast dextran crude extract for taking step 2) to obtain
Filling addition extraction auxiliary agent maintains pH to stablize；
Step 4) is dry: heating enzyme deactivation obtains enzymolysis liquid and obtains supernatant after separation, and dry supernatant obtains yeast Portugal
Glycan.
Preferably, alkali carries method in the step 2) are as follows: be stirred to react after mixing Saccharomyces cerevisiae with extraction auxiliary agent；More
Preferably, the reaction time is 30min~60min, and reaction temperature is 30 DEG C~60 DEG C.
Preferably, the weight ratio of the yeast dextran and probiotics is 1:1~5, more preferably 1:1~3.
Preferably, protease described in the step 3) is selected from one of cellulase, papain, pectase
Or it is a variety of；It is highly preferred that the protease is melon protease and cellulase complex enzyme.
Preferably, the enzymolysis liquid of the step 4) is centrifuged acquisition supernatant, supernatant is freeze-dried and is obtained
Yeast dextran.
Preferably, the mass fraction of the extraction auxiliary agent is 20~80%, quality dosage is Saccharomyces cerevisiae powder
10-60 times of quality, preferably 30-40 times.
Preferably, rotational speed of ball-mill is 20-500rpm, preferably 20-100rpm；Ball-milling Time is 10-60min, preferably 30-
40min, preferably, the grinding aid is selected from sodium chloride, sodium hydroxide, sodium bicarbonate, sodium hydrogensulfite and sulphur
One kind of sour hydrogen sodium solid or two kinds or more；Grinding aid helps salt or the alkalization of breaking-wall cell and intracellular organic matter outflow
Close object.
Preferably, the probiotics is bifidobacterium adolescentis, bifidobacterium longum, bifidobacterium breve, acidophilus lactic acid bar
Bacterium, Raman Bacillus acidi lactici, Lactobacillus casei, Lactobacillus rhamnosus, animal bifidobacteria, bifidobacterium thermophilum, leukonid
It is one such or a variety of；
The present invention is divided from yeast cells using the method that chaotropic agent self-dissolving, mechanochemistry auxiliary and enzyme induction combine
From yeast dextran is obtained, Constipated mice is caused using Loperamide, utilizes mice with constipation model evaluation yeast dextran
And the cooperation prescription of probiotics prevent constipation effect in vivo, it finally found that glucan leads Loperamide with probiotics compatibility
The constipation of cause have good prevention effect, while to restore intestinal microecology balance play the role of it is preferable, the party have work
Dosage is low, administration number of times is few and is easy to the advantages that extracting preparation, for prevent constipation and improve intestinal flora it is unbalance provide it is new
Selection.
The present invention is milled after mixing yeast powder with ball-milling additive with tumbling ball mill, is mentioned using alkaline extraction
It takes and protease purification, gained extracting solution obtains yeast dextran freeze-dried powder by freeze-drying.Made with Loperamide Hydrochloride
For modeling drug, the preparation of Constipation Model is carried out using Balb/c mouse as experimental animal.On the basis of this model, ferment is given in stomach-filling
Female glucan and Bifidobacterium probiotics carry out preventive administration treatment, gastrointestinal motility ability and defecation feelings to constipation
Condition inquires into the prevention effect for the Constipation Model mouse that yeast dextran combined hearth-care bacterium induces Loperamide.In order to further
Glucan and probiotics are studied to the mechanism of action of prevent constipation and adjusting intestinal flora.Simultaneously using HS/GC/MS to mouse excrement
Just short chain fatty acids (SCFA) are measured, and are measured using 16S RNA high-flux sequence to mouse intestinal flora.Knot
Fruit shows that yeast dextran joint probiotics can effectively prevent constipation of slow-remove type symptom caused by Loperamide, can promote stomach
Intestines peristalsis adjusts the expression of Serum IL-18, Nrf-2 and HO-1 etc., show glucan have improve mouse autoimmunity and
The effect of oxidation resistance improves the resistance to disease to mouse, including the enteron aisle for resisting Loperamide intervention induction
Power inhibits and motility, achievees the effect that prevent constipation.While by increased faecal short chain fatty acid type and containing
Amount and intestinal flora diversity may indicate that glucan may be by maintaining this potential machine of intestinal flora microecological balance
System, achievees the effect that prevent constipation more preferably than chemicals.
The present invention researches show that yeast dextran combination probiotic group at prebiotics functional health-care food have it is effective
Prevent constipation and adjust intestinal flora effect, and have effective dose it is low, administration number of times it is few and be easy to extract preparation etc. it is excellent
Point implies that yeast dextran can be used as a kind of novel functionality food applied to clinical prevention constipation in conjunction with probiotics
Product, health care product or drug.
Detailed description of the invention:
Fig. 1 is mice with constipation intestinal flora and blank group and model group comparison Venn after 5 yeast dextran of test example is intervened
Figure；
Fig. 2 is mice with constipation intestinal flora and blank group and model group comparison Venn after 6 yeast dextran of test example is intervened
Figure；
Fig. 3 is mice with constipation intestinal flora and blank group and model group comparison Venn after 7 yeast dextran of test example is intervened
Figure；
Fig. 4 is mice with constipation intestinal flora and blank group and model group comparison Venn after 8 yeast dextran of test example is intervened
Figure；
Fig. 5 be after total therapeutic intervention mouse intestinal with blank group and model group comparison Venn figure；
Fig. 6 is mice with constipation serum HO-1 expression figure (A: test example 1 after yeast dextran is intervened；B: test example 2；
C: test example 3；D: test example 4)；
Fig. 7 is mice with constipation serum N rf-2 expression figure (A: test example 1 after yeast dextran is intervened；B: test example 2；
C: test example 3；D: test example 4)；
Fig. 8 is mice with constipation Serum IL-18 expression figure (A: test example 1 after yeast dextran is intervened；B: test example 2；
C: test example 3；D: test example 4)；
Fig. 9 is total compound information of mice with constipation faecal short chain fatty acid after 1 yeast dextran of test example is intervened；
Figure 10 is total compound information of mice with constipation faecal short chain fatty acid after 2 yeast dextran of test example is intervened；
Figure 11 is total compound information of mice with constipation faecal short chain fatty acid after 3 yeast dextran of test example is intervened；
Figure 12 is total compound information of mice with constipation faecal short chain fatty acid after 4 yeast dextran of test example is intervened；
Figure 13 is total compound information of blank control group mouse faecal short chain fatty acid；
Figure 14 is total compound information of mice with constipation intestines faecal short chain fatty acid.
Specific embodiment
The present invention program is described further combined with specific embodiments below, but protection scope of the present invention and not only
It is limited to this.
In following case study on implementation in yeast dextran protein measuring method are as follows:
The measurement of protein: using Kjeldahl's method, referring to GB/T5009.5-2003 " measurement of Protein in Food "；
The measurement of ash content: using calcination Weight, referring to GB/T 5009.4-2003 " measurement of ash content in food "；The survey of moisture
It is fixed: direct drying method to be used, referring to GB/T 5009.3-2003 " measurement of moisture in food ".
In following case study on implementation in yeast dextran polysaccharide content assaying method are as follows:
Sample 10mg is weighed, the H of 5ml 8mol/L is first used2SO4After hydrolyzing 5min, it is diluted with water to 1.5mol/L, in 100
3h is hydrolyzed at DEG C, after being cooled to room temperature, is settled to 250mL, is weighed 1.0mL and is measured by Phenol sulfuric acid procedure.
In formula, X --- callose content
C --- concentration of glucose in sample hydrolyzate, g/mL；
V --- sample hydrolyzate constant volume；
The quality of M --- sample, g；
F --- 0.9 is converted into the coefficient of glucan for glucose.
One, the preparation of yeast dextran
Embodiment 1
Step 1) ball grinds: 10g Saccharomyces cerevisiae powder and grinding aid sodium hydrate solid are sufficiently mixed, grinding aid
Additive amount be mass fraction 20%, be placed in tumbling ball mill, 30 medium size ball milling pearls be added, with ball mill carry out ball milling
It extracts, revolving speed 100rpm, mixed grinding 30min；
Step 2) alkali carries: being to extract solution with NaOH solution, and NaOH solution mass fraction is 20%, and quality dosage is face
30 times of the quality of packet yeast powder carry out secondary alkali carries to yeast powder, extract 40min at 40 DEG C, it is thick to obtain yeast dextran
Extract；
Suitable papain, enzymatic hydrolysis purifying is added in step 3) purifying in yeast dextran crude extract, and uses 1mol/
The NaOH solution of L maintains pH constant, obtains enzymolysis liquid；
Step 4) is dry: enzymolysis liquid being put into boiling water bath, enzyme deactivation 10min is heated, enzymolysis solution after enzyme deactivation is centrifuged
Machine centrifugation, revolving speed 1000rpm are centrifuged 10min, obtain supernatant；Supernatant is freeze-dried, the ferment of higher degree is obtained
Female glucan；The protein content of obtained high-purity yeast dextran is 6.23%, and polyoses content reaches 79.20%.
Embodiment 2
Step 1) ball grinds: 10g Saccharomyces cerevisiae powder and grinding aid sodium hydrate solid are sufficiently mixed, grinding aid
Additive amount be mass fraction 40%, be placed in tumbling ball mill, 30 medium size ball milling pearls be added, with ball mill carry out ball milling
It extracts, revolving speed 100rpm, mixed grinding 30min；
Step 2) alkali carries: using NaOH solution as Extraction solvent, mass fraction 30%, quality dosage is Saccharomyces cerevisiae powder
30 times of quality；Secondary microwave alkali carries are carried out to yeast powder, 40min is extracted at 40 DEG C, obtains yeast dextran crude extract；
Suitable papain, enzymatic hydrolysis purifying is added in step 3) purifying in yeast dextran crude extract, and uses 1mol/
The NaOH solution of L maintains pH constant, obtains enzymolysis liquid；
Step 4) is dry: enzymolysis liquid being put into boiling water bath, enzyme deactivation 10min is heated, enzymolysis solution after enzyme deactivation is centrifuged
Machine centrifugation, revolving speed 1000rpm are centrifuged 10min, obtain supernatant；Supernatant is freeze-dried, the ferment of higher degree is obtained
Female glucan；The protein content of obtained yeast dextran is 6.08%, and polyoses content reaches 74.28%.
Embodiment 3
Step 1) ball grinds: 10g Saccharomyces cerevisiae powder and grinding aid solid sodium chloride are sufficiently mixed, grinding aid
Additive amount is mass fraction 80%, is placed in tumbling ball mill, 30 medium size ball milling pearls are added, and carries out ball milling with ball mill and mentions
It takes, revolving speed 100rpm, mixed grinding 30min；
Step 2) alkali carries: using NaOH solution as Extraction solvent, mass fraction 40%, quality dosage is Saccharomyces cerevisiae powder
40 times of quality.Secondary microwave alkali carries are carried out to yeast powder, 40min is extracted at 40 DEG C, obtains yeast dextran crude extract；
Suitable cellulase, enzymatic hydrolysis purifying is added in step 3) purifying in yeast dextran crude extract, and uses 1mol/L
NaOH solution maintain pH it is constant, obtain enzymolysis liquid；
Step 4) is dry: enzymolysis liquid being put into boiling water bath, enzyme deactivation 10min is heated, enzymolysis solution after enzyme deactivation is centrifuged
Machine centrifugation, revolving speed 1000rpm are centrifuged 10min, obtain supernatant；Supernatant is freeze-dried, the ferment of higher degree is obtained
Female glucan；The protein content of obtained yeast dextran is 5.65%, and polyoses content reaches in yeast dextran
81.74%.
Embodiment 4
Step 1) ball grinds: 10g Saccharomyces cerevisiae powder and grinding aid sodium hydrate solid are sufficiently mixed, grinding aid
Additive amount be mass fraction 40%, be placed in tumbling ball mill, 30 medium size ball milling pearls be added, with ball mill carry out ball milling
It extracts, revolving speed 100rpm, mixed grinding 30min；
Step 2) alkali carries: using NaOH solution as Extraction solvent, mass fraction 50%, quality dosage is Saccharomyces cerevisiae powder
40 times of quality；Secondary microwave alkali carries are carried out to yeast powder, 40min is extracted at 40 DEG C, obtains yeast dextran crude extract；
Suitable papain and cellulase complex enzyme, enzyme is added in step 3) purifying in yeast dextran crude extract
Solution purifying, and maintain pH constant with the NaOH solution of 1mol/L, obtain enzymolysis liquid；
Step 4) is dry: enzymolysis liquid being put into boiling water bath, enzyme deactivation 10min is heated, enzymolysis solution after enzyme deactivation is centrifuged
Machine centrifugation, revolving speed 1000rpm are centrifuged 10min, obtain supernatant；Supernatant is freeze-dried, the ferment of higher degree is obtained
Female glucan；The protein content of obtained yeast dextran is 5.27%, and polyoses content reaches in yeast dextran
89.13%.
Two, test is investigated in the defecating feces excretion of yeast dextran combination probiotic group and adjusting intestinal flora effect
The early-stage preparations of drug in following case study on implementation are as follows:
Physiological saline, Loperamide Hydrochloride, yeast dextran, 5% gum arabic and active carbon.
Animal intestinal tract parametric measurement method in following case study on implementation are as follows:
The measurement of mice with constipation enteron aisle propulsion rate: to after Loperamide Hydrochloride 0.5 hour, dosage group is given respectively containing corresponding
The prepared Chinese ink (active powdered carbon, 10% gum arabic containing 5%) of given the test agent is negative and model control group gives prepared Chinese ink stomach-filling.25 points
Cervical dislocation puts to death animal immediately after clock, opens abdominal cavity and separates mesenterium, clip upper end from the intestinal tube of pylorus, lower end to ileocecus,
It is placed on pallet, small intestine is gently pulled into straight line, measurement Length of intestine is " total small intestinal length ", is from pylorus to prepared Chinese ink forward position
" prepared Chinese ink propulsion length ", is calculated as follows ink progradation:
The assessment of mouse defecation condition: it after the administration of each group intragastric administration on mice, is immediately transferred into the metabolic cage for being lined with filter paper, prohibits
Food can't help water, observe and record the first grain melena event of exclusion of every mouse in 5 hours, defecation granule number, stool weight；Observation
After, measurement excrement dry weight (weight after 80 DEG C of drying for 24 hours).Excrement water content is calculated according to following formula:(wherein m1, m2 are respectively excrement weight in wet base and excrement dry weight).
The assay of gastrointestinal hormone in mice with constipation serum: supernatant obtained by each group in Intestinal pushing experiment is taken, to IL-
18, Nrf-2, HO-1 content are measured.
The measuring method of faecal short chain fatty acid in following case study on implementation are as follows:
Fecal specimens processing: accurately weighing 100mg fecal specimens, 0.9ml 0.01mol/L PBS buffer solution is added, sufficiently
Dissolution after the 6% phosphoric acid mixing of 1/6 volume is added, is being added 1ml ether, is shaking 10min, and 3000rpm is centrifuged 5min, takes
Ether layer is added anhydrous calcium chloride and removes moisture, takes 2 microlitres of sample 7697A-7890B-5977B gas chromatography-mass spectrographies
Instrument (Aglient company, the U.S.) measurement.
Chromatographic condition: DB-624UI capillary column (30m x 0.25mm, 1.40 μm, middle polar column)；Injector temperature:
250℃；Carrier gas is He gas；Temperature programming condition: 50 DEG C of initial temperature, 1min is kept, is warming up to 200 with the rate of 10 DEG C/min
DEG C, keep 10min；Column flow: 1mL/min；Headspace sampling, ml headspace bottle equilibrium temperature is 100 DEG C, equilibration time 25min, fixed
110 DEG C of circumstance temperature degree of amount, 120 DEG C of transmission line temperature, split ratio 10:1
Mass Spectrometry Conditions: it 280 DEG C of junction temperature, electron energy 70eV, 230 DEG C of ion source temperature, scanning mode: sweeps entirely
It retouches；Solvent delay 0；Compose library NIST 17.
Specification Curve of Increasing: precision, which weighs acetic acid, propionic acid, butyric acid and adds diethyl ether, is made the solution containing about 0.5mg/mL respectively,
For stock solution.Take stock solution and inner mark solution, be configured to ultimate density containing standard items it is each 1000,400,200,100,50,10,
The serial solution (each containing the internal standard 50ug/mL) of 5ug/mL, sample introduction is analyzed.Using reference substance and the ratio of internal standard compound concentration as abscissa,
Corresponding peak area ratio is ordinate, draws standard curve
Data Processing in Experiment: each group experimental data uses mean ± standard deviation (mean ± SD) to indicate, single factor test variance point
Analysis；P < 0.05 indicates that two groups of differences are statistically significant.
Test example 1
Balb/c mouse 30 are taken, 3 groups in total, every group 10, male, 18~22g of weight, continuous 4 weeks stomach-filling glucans
(10mg/kg weight comes from embodiment 1), Bifidobacterium probiotics (30mg/kg weight), model group and blank group are not processed,
The isometric physiological saline of stomach-filling.After four weeks, glucan group and model group stomach-filling Loperamide Hydrochloride (10mg/kg) 5 days, blank group
(No group) not modeling, does same treatment with physiological saline.Record the daily behavior situation of each group mouse.When melena is arranged in measurement for the first time
Between, intestinal transport rate, stool weight, excrement water content and short chain fatty acids, Serum IL-18, OH-1, Nrf-2 expression.
Experimental result can be shown in Table 1 and Fig. 3,4, and interpretation of result shows normally to organize compared with model group, and loperamide can be shown
The gastrointestinal motility power for inhibiting mouse is write, and extends defecation time, is inhibited defecation (quantity, weight) (P < 0.05), glucan knot
Closing probiotics can obviously prevent constipation situation caused by loperamide, significantly improve the gastrointestinal motility power of mice with constipation,
And shorten defecation time, increase defecation (P < 0.05), in addition, compared to normal group, IL- relevant to immunocompetence in model group
18 are decreased obviously, and faecal short chain fatty acid type and content decline (P < 0.05).It is right after glucan and probiotics prevention administration
The expression quantity of excrement SCFA and intestine immunity and oxidation resistance related gene IL-18, OH-1, Nrf-2 have obvious restore
Effect, and the content of glucan group IL-18 has no and is decreased obviously, visible Fig. 6~8 of experimental result；With reference to Fig. 9~14, glucan
And faecal short chain fatty acid type and content after probiotics prevention administration.
Test example 2
BALb/c mouse 30 are taken, 3 groups in total, every group 10, male, 18~22g of weight, continuous 4 weeks stomach-filling glucans
(20mg/kg weight comes from embodiment 2), Bifidobacterium probiotics (50mg/kg weight), model group and blank group are not processed,
The isometric physiological saline of stomach-filling.After four weeks, glucan group and model group stomach-filling Loperamide Hydrochloride (10mg/kg) 5 days, blank group
(No group) not modeling, does same treatment with physiological saline.Record the daily behavior situation of each group mouse.When melena is arranged in measurement for the first time
Between, intestinal transport rate, stool weight, excrement water content and short chain fatty acids, Serum IL-18, OH-1, Nrf-2 expression.
Experimental result can be shown in Table 1 and Fig. 3,4, and interpretation of result shows normally to organize compared with model group, and loperamide can be shown
The gastrointestinal motility power for inhibiting mouse is write, and extends defecation time, is inhibited defecation (quantity, weight) (P < 0.05), glucan knot
Closing probiotics can obviously prevent constipation situation caused by loperamide, significantly improve the gastrointestinal motility power of mice with constipation,
And shorten defecation time, increase defecation (P < 0.05), in addition, compared to normal group, IL- relevant to immunocompetence in model group
18 are decreased obviously, and faecal short chain fatty acid type and content decline (P < 0.05).It is right after glucan and probiotics prevention administration
The expression quantity of excrement SCFA and intestine immunity and oxidation resistance related gene IL-18, OH-1, Nrf-2 have apparent extensive
Multiple effect, and the content of glucan group IL-18 has no and is decreased obviously, visible Fig. 6~8 of experimental result；With reference to Fig. 9~14, Portugal is poly-
Faecal short chain fatty acid type and content after sugar and probiotics prevention administration.
Test example 3
Balb/c mouse 30 are taken, 3 groups in total, every group 10, male, 18~22g of weight, continuous 4 weeks stomach-filling glucans
(25mg/kg weight comes from embodiment 3), Bifidobacterium probiotics (50mg/kg weight), the isometric physiological saline of stomach-filling.Surrounding
Afterwards, glucan group and model group stomach-filling Loperamide Hydrochloride (10mg/kg) 5 days, physiological saline is used in blank group (No group) not modeling
Do same treatment.Record the daily behavior situation of each group mouse.Measurement for the first time arrange the melena time, intestinal transport rate, stool weight,
Excrement water content and short chain fatty acids, Serum IL-18, OH-1, Nrf-2 expression.
Experimental result can be shown in Table 1 and Fig. 3,4, and interpretation of result shows normally to organize compared with model group, and loperamide can be shown
The gastrointestinal motility power for inhibiting mouse is write, and extends defecation time, is inhibited defecation (quantity, weight) (P < 0.05), glucan knot
Closing probiotics can obviously prevent constipation situation caused by loperamide, significantly improve the gastrointestinal motility power of mice with constipation,
And shorten defecation time, increase defecation (P < 0.05), in addition, compared to normal group, IL- relevant to immunocompetence in model group
18 are decreased obviously, and faecal short chain fatty acid type and content decline (P < 0.05).It is right after glucan and probiotics prevention administration
The expression quantity of excrement SCFA and intestine immunity and oxidation resistance related gene IL-18, OH-1, Nrf-2 have apparent extensive
Multiple effect, and the content of glucan group IL-18 has no and is decreased obviously, visible Fig. 6~8 of experimental result；With reference to Fig. 9~14, Portugal is poly-
Faecal short chain fatty acid type and content after sugar and probiotics prevention administration.
Test example 4
Balb/c mouse 30 are taken, 3 groups in total, every group 10, male, 18~22g of weight, continuous 4 weeks stomach-filling glucans
(25mg/kg weight comes from embodiment 4), Bifidobacterium probiotics (30mg/kg weight), model group and blank group are not processed,
The isometric physiological saline of stomach-filling.After four weeks, glucan group and model group stomach-filling Loperamide Hydrochloride (10mg/kg) 5 days, blank group
(No group) not modeling, does same treatment with physiological saline.Record the daily behavior situation of each group mouse.When melena is arranged in measurement for the first time
Between, intestinal transport rate, stool weight, excrement water content and short chain fatty acids, Serum IL-18, OH-1, Nrf-2 expression.
Experimental result can be shown in Table 1, and interpretation of result shows normally to organize compared with model group, and loperamide can significantly inhibit small
The gastrointestinal motility power of mouse, and extend defecation time, inhibit defecation (quantity, weight) (P < 0.05), glucan binding domian probiotics
It can obviously prevent constipation situation caused by loperamide, significantly improve the gastrointestinal motility power of mice with constipation, and shorten row
Just the time increases defecation (P < 0.05), in addition, compared to normal group, under IL-18 relevant to immunocompetence is obvious in model group
Drop, faecal short chain fatty acid type and content decline (P < 0.05).After glucan and probiotics prevention administration, to excrement SCFA
And the expression quantity of intestine immunity and oxidation resistance related gene IL-18, OH-1, Nrf-2 have apparent restitution, and
The content of glucan group IL-18, which has no, to be decreased obviously, visible Fig. 6~8 of experimental result；With reference to Fig. 9~14, glucan and probiotics
Faecal short chain fatty acid type and content after prevention administration.
The excrement parameter situation of 1 Loperamide of table cause mice with constipation
(A: test example 1；B: test example 2；C: test example 3；D: test example 4
* indicate there is significant difference compared with model group, p < 0.05, * * expression have extremely significant difference, p compared with model group
< 0.01, # indicate variant with blank group, and p < 0.05, ## expression have extremely significant difference, p < 0.01 compared with model group.)
Three, glucan binding domian Bifidobacterium to prevent constipation and adjusts intestinal flora effect investigation test
Microbial population of animal intestinal tract measuring method in following case study on implementation are as follows:
Mice with constipation intestinal flora high throughput assay: excrement is taken to carry out 16S rRNA gene magnification and high-flux sequence.With
Sample total DNA is template, uses 16S rRNA gene universal primer 338F (the 5 '-ACTCCTACGGGAGGCAGC AG- of bacterium
3) hypervariable region the V3-V5 gene of 16S rDNA therein is expanded with 806R (5-GGACTACHVGGGTWTCTAAT-3 ').
It can activity classification unit analysis OTU and Phylogenetic Analysis: being 0.03 to divide OTU according to sequence difference, statistics is every
The sequence number of a OTU, OTU of the sequence ratio greater than 10% will be used for subsequent analysis.Statistics only has the OTU of a sequence, presses
It is calculated according to C=(1- (n1/N)) * 100.Wherein, the GenBank database of itself and NCBI are carried out Blast to compare, by result
In have determine classification information sequence downloading after be compared with ClustalX, Neighbour-joining method building system
System development tree, bootstrap value are 1000.
Data Processing in Experiment: what MiSeq was sequenced is both-end sequence data, first according between PE reads
Overlap relationship, by pairs of reads splicing (merge) at a sequence, while the effect of the quality and merge to reads
Quality Control filtering is carried out, sample is distinguished according to the barcode at sequence head and the tail both ends and primer sequence and obtains ordered sequence, and corrects sequence
Column direction, as optimization data.Each group experimental data uses mean ± standard deviation (mean ± SD) to indicate, single factor test variance point
Analysis.P < 0.05 indicates that two groups of differences are statistically significant.
Test example 5
Balb/c mouse 30 are taken, 3 groups in total, every group 10, male, 18~22g of weight, continuous 4 weeks stomach-filling glucans
(10mg/kg weight comes from embodiment 1), Bifidobacterium probiotics (30mg/kg weight), model group and blank group are not processed,
The isometric physiological saline of stomach-filling.After four weeks, glucan group and model group stomach-filling Loperamide Hydrochloride (10mg/kg) 5 days, blank group
(No group) not modeling, does same treatment with physiological saline.Record the daily behavior situation of each group mouse.Fecal specimens are taken to be used for
16s rRNA high-flux sequence, and data analysis is carried out by PCoA and PLS-DA etc..
Visible Fig. 1~5 of experimental result, interpretation of result show that intestinal flora diversity and composed structure are substantially change, explanation
Glucan binding domian probiotic group can dramatically increase the adjusting for promoting gastrointestinal bacterial flora, and resist intestinal flora caused by constipation
Unbalance (P < 0.05).
Test example 6
Balb/c mouse 30 are taken, 3 groups in total, every group 10, male, 18~22g of weight, continuous 4 weeks stomach-filling glucans
(20mg/kg weight comes from embodiment 2), Bifidobacterium probiotics (50mg/kg weight), model group and blank group are not processed,
The isometric physiological saline of stomach-filling.After four weeks, glucan group and model group stomach-filling Loperamide Hydrochloride (10mg/kg) 5 days, blank group
(No group) not modeling, does same treatment with physiological saline.Record the daily behavior situation of each group mouse.Fecal specimens are taken to be used for
16s rRNA high-flux sequence, and data analysis is carried out by PCoA and PLS-DA etc..
Visible Fig. 1~5 of experimental result, interpretation of result show that intestinal flora diversity and composed structure are substantially change, explanation
Glucan binding domian probiotic group can dramatically increase the adjusting for promoting gastrointestinal bacterial flora, and resist intestinal flora caused by constipation
Unbalance (P < 0.05).
Test example 7
Balb/c mouse 30 are taken, 3 groups in total, every group 10, male, 18~22g of weight, continuous 4 weeks stomach-filling glucans
(25mg/kg weight comes from embodiment 3), Bifidobacterium probiotics (50mg/kg weight), model group and blank group are not processed,
The isometric physiological saline of stomach-filling.After four weeks, glucan group and model group distinguish stomach-filling Loperamide Hydrochloride (10mg/kg) 5 days, empty
White group of (No group) not modeling, does same treatment with physiological saline.Record the daily behavior situation of each group mouse.Fecal specimens are taken to use
Data analysis is carried out in 16s rRNA high-flux sequence, and by PCoA and PLS-DA etc..
Visible Fig. 1~5 of experimental result, interpretation of result show that intestinal flora diversity and composed structure are substantially change, explanation
Glucan binding domian probiotic group can dramatically increase the adjusting for promoting gastrointestinal bacterial flora, and resist intestinal flora caused by constipation
Unbalance (P < 0.05).
Test example 8
Balb/c mouse 30 are taken, 3 groups in total, every group 10, male, 18~22g of weight, continuous 4 weeks stomach-filling glucans
(25mg/kg weight comes from embodiment 4), Bifidobacterium probiotics (30mg/kg weight), model group and blank group are not processed,
The isometric physiological saline of stomach-filling.After four weeks, glucan group and model group stomach-filling Loperamide Hydrochloride (10mg/kg) 5 days, blank group
(No group) not modeling, does same treatment with physiological saline.Record the daily behavior situation of each group mouse.Fecal specimens are taken to be used for
16s rRNA high-flux sequence, and data analysis is carried out by PCoA and PLS-DA etc..
Visible Fig. 1~5 of experimental result, interpretation of result show that intestinal flora diversity and composed structure are substantially change, explanation
Glucan binding domian probiotic group can dramatically increase the adjusting for promoting gastrointestinal bacterial flora, and resist intestinal flora caused by constipation
Unbalance (P < 0.05).
Claims (10)
1. middle application of the yeast dextran composition in preparation for the drug, food and health care product of prevent constipation, wherein institute
Stating composition includes yeast dextran and probiotics, and the weight ratio of the yeast dextran and probiotics is 1:1~10,
And yeast dextran is prepared by the following method acquisition:
Step 1) ball grinds: ball-milling treatment is carried out after high activity Saccharomyces cerevisiae and grinding aid are mixed, obtains Saccharomyces cerevisiae
Powder；
Step 2) alkali carries: Saccharomyces cerevisiae powder is extracted using auxiliary agent is extracted, and obtains yeast dextran crude extract, wherein described to mention
Auxiliary agent is taken to be selected from one of sodium chloride, sodium hydroxide, sodium bicarbonate, sodium hydrogensulfite and sodium bisulphate solution or two
Kind or more；
Step 3) purifying: protease hydrolyzed is added in the yeast dextran crude extract for taking step 2) to obtain, wherein is added by supplement
Entering to extract auxiliary agent maintains pH to stablize；
Step 4) is dry: heating enzyme deactivation obtains enzymolysis liquid and obtains supernatant after separation, and dry supernatant obtains yeast dextran.
2. application according to claim 1, it is characterised in that: alkali carries method in the step 2) are as follows: by Saccharomyces cerevisiae with
Extraction auxiliary agent is stirred to react after mixing or microwave reaction；It is highly preferred that the reaction time is 30min~60min, reaction temperature is
30 DEG C~60 DEG C.
3. application according to claim 2, it is characterised in that: the weight ratio of the yeast dextran and probiotics
For 1:1~5, preferably 1:1~3.
4. application according to claim 1, it is characterised in that: the protease in the step 3) is selected from cellulase, wood
One or more of melon protease, pectase.
5. application according to claim 4, it is characterised in that: the protease is that papain and cellulase are multiple
Synthase.
6. application according to claim 1, it is characterised in that: the enzymolysis liquid of the step 4) is centrifuged acquisition supernatant
Supernatant is freeze-dried and obtains yeast dextran by liquid.
7. application according to claim 1, it is characterised in that: the mass fraction of the extraction auxiliary agent is 20~80%,
Its quality dosage is 10-60 times of the quality of Saccharomyces cerevisiae powder.
8. application according to claim 7, it is characterised in that: the quality dosage of the extraction auxiliary agent is Saccharomyces cerevisiae
30-40 times of the quality of powder.
9. application according to claim 1, it is characterised in that: the probiotics is bifidobacterium adolescentis, long bifid bar
Bacterium, bifidobacterium breve, Lactobacillus acidophilus, Raman Bacillus acidi lactici, Lactobacillus casei, Lactobacillus rhamnosus, animal bifid bar
Bacterium, bifidobacterium thermophilum, leukonid are one such or a variety of.
10. application according to claim 1, it is characterised in that: the constipation is constipation of slow-remove type.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910172666.8A CN110025639A (en) | 2019-03-07 | 2019-03-07 | Application of the yeast dextran composition in prevent constipation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910172666.8A CN110025639A (en) | 2019-03-07 | 2019-03-07 | Application of the yeast dextran composition in prevent constipation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110025639A true CN110025639A (en) | 2019-07-19 |
Family
ID=67235860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910172666.8A Pending CN110025639A (en) | 2019-03-07 | 2019-03-07 | Application of the yeast dextran composition in prevent constipation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110025639A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998026787A1 (en) * | 1996-12-19 | 1998-06-25 | The University Of New South Wales | Prebiotics and probiotics |
| US20090148414A1 (en) * | 2005-11-21 | 2009-06-11 | Bioatlantis Limited | Novel Composition to Improve Gut Health and Animal Performance and Methods of Making the Same |
| CN105454966A (en) * | 2015-12-11 | 2016-04-06 | 苏州泽达兴邦医药科技有限公司 | Probiotics solid beverage for improving gastrointestinal tract and immunity and preparation method thereof |
| CN107647397A (en) * | 2017-08-31 | 2018-02-02 | 广州富诺营养科技有限公司 | A kind of probiotic powder and preparation method thereof |
| CN109718256A (en) * | 2018-12-14 | 2019-05-07 | 浙江九如堂生物科技有限公司 | For improving the unbalance composition and its preparation method and application of intestinal flora |
-
2019
- 2019-03-07 CN CN201910172666.8A patent/CN110025639A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998026787A1 (en) * | 1996-12-19 | 1998-06-25 | The University Of New South Wales | Prebiotics and probiotics |
| US20090148414A1 (en) * | 2005-11-21 | 2009-06-11 | Bioatlantis Limited | Novel Composition to Improve Gut Health and Animal Performance and Methods of Making the Same |
| CN105454966A (en) * | 2015-12-11 | 2016-04-06 | 苏州泽达兴邦医药科技有限公司 | Probiotics solid beverage for improving gastrointestinal tract and immunity and preparation method thereof |
| CN107647397A (en) * | 2017-08-31 | 2018-02-02 | 广州富诺营养科技有限公司 | A kind of probiotic powder and preparation method thereof |
| CN109718256A (en) * | 2018-12-14 | 2019-05-07 | 浙江九如堂生物科技有限公司 | For improving the unbalance composition and its preparation method and application of intestinal flora |
Non-Patent Citations (1)
| Title |
|---|
| 宫艳艳等: "不同提取方法对酵母葡聚糖性质的影响", 《食品工业科技》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11278580B2 (en) | Methods and compositions relating to microbial treatment and diagnosis of disorders | |
| CN109789173B (en) | Nanovesicles derived from bacillus bacteria and uses thereof | |
| JP2020532515A (en) | Methods and compositions for the treatment of microbiome-related disorders | |
| Rawi et al. | Manipulation of gut microbiota using acacia gum polysaccharide | |
| CN102711778B (en) | Method for reducing gastro-intestinal inflammation using bifidobacterium animalis bacteria or a fermented dairy product comprising such bacteria | |
| CN109718256A (en) | For improving the unbalance composition and its preparation method and application of intestinal flora | |
| JP5554994B2 (en) | Lactic acid bacteria-containing preparation | |
| CN112841317B (en) | Nutritional composition suitable for infants fed by elderly puerperae | |
| CN110325198A (en) | The purposes in psoriasis is being treated and/or prevented to probiotics | |
| CN1980682A (en) | Flaxseeds for body weight management | |
| CN108433114A (en) | It is a kind of that there is the composite food fiber powder and preparation method for adjusting intestinal flora function | |
| CN104415060A (en) | Edible composition as well as preparation method and application thereof | |
| EP3962295A1 (en) | Probiotic bacterial strains that produce short chain fatty acids and compositions comprising same | |
| EP4081231A1 (en) | Compositions comprising microbes and methods of use and making thereof | |
| KR20200138333A (en) | Compositions and methods for treating inflammatory bowel disease | |
| CN104415061A (en) | Edible composition as well as preparation method and application thereof | |
| CN111565734A (en) | Therapeutic use of lactobacillus plantarum | |
| CN112931883A (en) | Prebiotic composition and preparation method and application thereof | |
| CN106310006A (en) | Application of composition packet in preparing food, medicines, health care products and nutrition for improving and treating human Prader-Willi syndrome | |
| CN101297820A (en) | Streptococcus faecium function signal molecule formulation and product thereof for reducing fat and slimming | |
| CN110025639A (en) | Application of the yeast dextran composition in prevent constipation | |
| CN110156910A (en) | Yeast dextran extract, composition and the application in preparation prevent constipation preparation | |
| CN109938340A (en) | A kind of compound probiotic composition with strengthen immunity | |
| CN111448306A (en) | Anaerobic clavulanate (Anaerofuss stercoris) and application thereof | |
| TW202045715A (en) | Novel lactic acid bacterium, and composition containing same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190719 |